Product image of Influsplit Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202) supplied by GNH India

Influsplit Tetra

Active Ingredient:
B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202
Origin:
EU

Influsplit Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

B/Phuket/3073/2013-like Virus, the active ingredient in Influsplit Tetra, is a vaccine presented as a split‑virion formulation for intramuscular use. It helps prevent influenza infection caused by the B/Phuket/3073/2013-like and B/Austria/1359417/202 strains and contributes to seasonal influenza prophylaxis in the general population.

GNH India supplies Influsplit Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Glaxosmithkline Gmbh & Co. Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Influsplit Tetra is a quadrivalent influenza vaccine used to protect against influenza B virus infections.
  • Prevention of influenza B infection (B/Phuket/3073/2013-like): reduces incidence of illness caused by this strain.
  • Prevention of influenza B infection (B/Austria/1359417/202): reduces incidence of illness caused by this strain.
  • Seasonal influenza prophylaxis: provides broader protection against circulating influenza viruses during the flu season.

How It Works

  • Influsplit Tetra contains split virion particles of the specified influenza B strains. After intramuscular injection, the viral antigens are taken up by antigen‑presenting cells, which process and display them to T lymphocytes. This stimulates a humoral immune response, leading to the production of strain‑specific neutralising antibodies and the generation of immunological memory, thereby conferring active immunity against subsequent exposure to the matched influenza viruses.

Side Effects

Like other influenza vaccines, Influsplit Tetra may be associated with local and systemic reactions.

Common Side Effects

  • Pain at injection site: mild to moderate soreness.
  • Redness or swelling at injection site.
  • Low‑grade fever.
  • Headache.
  • Muscle aches.
  • Fatigue.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurological disorder.
  • Seizures: especially in children with a history of febrile seizures.
  • High‑grade fever >39°C.
  • Persistent vomiting.
  • Severe local reaction with extensive swelling.

Precautions & Warnings

Before administering Influsplit Tetra, consider the following precautions.

  • Contraindication: severe allergic reaction to any component of the vaccine: do not vaccinate.
  • History of Guillain‑Barré syndrome: evaluate risk versus benefit before use.
  • Acute moderate or severe illness: postpone vaccination until recovery.
  • Pregnancy: vaccine may be administered if benefits outweigh potential risks; consult healthcare provider.
  • Immunocompromised patients: vaccine may be less effective; monitor response.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Influsplit Tetra can interact with other vaccines or immunomodulatory agents.

Major Interactions (Avoid)

  • Live attenuated vaccines: avoid co‑administration within 4 weeks to prevent interference.
  • Immunoglobulin therapy: may reduce vaccine efficacy if given within 2 weeks before or after vaccination.

Moderate Interactions (Monitor Closely)

  • Antipyretics (acetaminophen, ibuprofen): may blunt antibody response if taken prophylactically; use only for symptomatic relief.
  • Corticosteroids (systemic): may diminish immune response; assess timing.
  • Antiviral medications (oseltamivir): generally safe but monitor for any reduced immunogenicity.

Frequently Asked Questions

Influsplit Tetra is a split‑virion quadrivalent influenza vaccine indicated for the prevention of influenza B infections caused by the B/Phuket/3073/2013‑like and B/Austria/1359417/202 strains, as well as for general seasonal influenza prophylaxis in the broader population.

The B/Phuket/3073/2013‑like virus is presented as an inactivated, split‑virion antigen. After intramuscular injection, it is processed by antigen‑presenting cells, which activate T‑cells and stimulate B‑cells to produce strain‑specific neutralising antibodies, establishing active immunity against future exposure to the matching influenza virus.

The dose of Influsplit Tetra is determined by the prescribing healthcare professional. Typically, a single intramuscular injection is administered, but the exact volume and schedule depend on local immunisation guidelines and the patient’s age and health status.

Influsplit Tetra may be given to pregnant or breastfeeding individuals when the expected benefits outweigh any potential risks. Healthcare providers should evaluate each case individually and discuss the safety profile with the patient before vaccination.

To order Influsplit Tetra, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Influsplit Tetra is a split‑virion quadrivalent vaccine that specifically includes two influenza B strains, offering broader B‑type coverage compared with some trivalent formulations. Its safety and immunogenicity profile is comparable to other licensed quadrivalent vaccines, while the cold‑chain storage requirement aligns with standard practice for injectable vaccines.

Influsplit Tetra must be stored at 2‑8 °C in a refrigerator. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the product. Do not use the vaccine if it has been exposed to temperatures outside this range.

The vaccine is administered by a single intramuscular injection, usually into the deltoid muscle of the upper arm. The injection should be performed by a qualified healthcare professional using aseptic technique.

Serious adverse events, although rare, include anaphylaxis, Guillain‑Barré syndrome, high‑grade fever, seizures (particularly in children with a history of febrile seizures), and severe local reactions with extensive swelling. Any of these symptoms require immediate medical evaluation.

Individuals with a known severe allergy to any component of the vaccine or who have experienced a previous severe allergic reaction to a similar influenza vaccine should not receive Influsplit Tetra. Additionally, persons with a recent history of Guillain‑Barré syndrome should be evaluated carefully before vaccination.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT